Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany rak płuc z mutacją EGFR (typ exon 19 lub exon 21)
- •Nowa diagnoza od stycznia 2024 roku
✗ Disqualifies
- •Zły ogólny stan zdrowia (wynik ECOG 2 lub więcej)
- •Wcześniejsze leczenie lekami: osimertinib, amivantamab lub lazertinib
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Locations (9)
Pacific Cancer Care
Monterey, United States
Torrance Memorial Physician Network-Cancer Care
Torrance, United States
John Muir Health
Walnut Creek, United States
Bayhealth Cancer Center- Kent
Dover, United States
Bayhealth Cancer Center- Sussex
Milford, United States
Kootenai Clinic Cancer Services Coeur d'Alene
Coeur d'Alene, United States
Northwest Oncology & Hematology
Elk Grove Village, United States
Lankenau Medical Center
Paoli, United States
Oncology Consultants, P.A.
Houston, United States
Trial contact
N-Power Medicine Support
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.